Skip to main content
Clinical Trials/NCT00934726
NCT00934726
Completed
Not Applicable

Patient Satisfaction and Quality of Life Under Treatment With Seroquel XR

AstraZeneca0 sites150 target enrollmentJuly 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Quality of Life in Schizophrenia
Sponsor
AstraZeneca
Enrollment
150
Primary Endpoint
Subject wellbeing under Neuroleptics scale (Quality of Life)
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

Since subjective well-being and quality of life (QoL) are increasingly being recognized as important treatment outcomes in patients with schizophrenia (Hofer et al., 2004; Becker et al., 2005), the aim of this study is to investigate the effect of treatment with quetiapine XR on these parameters in the acute hospital and the subsequent ambulant care setting. The study is planned to be conducted in 15 centers all over Austria and, overall, about 150 inpatients with a ICD-10 diagnosis of acute schizophrenia are planning to be enrolled. The duration of the whole trial will be approximately 4 months, whereas 2 visits during hospitalization and two further visits after discharge will be scheduled. At each visit, adverse events and safety parameters, patient satisfaction and effectiveness of the current treatment, as well as concomitant medication and dosing schedules will be assessed and documented.In addition to that, the patients' overall satisfaction with antipsychotic therapy and their current quality of life will be determined using a QoL questionnaire, focussing on the subjective experience with quetiapine XR.

Registry
clinicaltrials.gov
Start Date
July 2009
End Date
October 2010
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult schizophrenia patients
  • Inclusion according to Summary of product characteristics

Exclusion Criteria

  • Diagnosis other than schizophrenia
  • Patients for which Seroquel XR is not registered (pregnant women, children and adolescents...)

Outcomes

Primary Outcomes

Subject wellbeing under Neuroleptics scale (Quality of Life)

Time Frame: 4 months

Secondary Outcomes

  • BPRS (Brief Psychiatric Rating Scale)(4 months)
  • CGI (Clinical Global Impression)(4 months)
  • All adverse events occurring during the study will be documented(4 months)

Similar Trials